BioSpace News Archive

New indication reflects distinct patient population in the REWIND study, including primarily people with multiple cardiovascular risk factors but without established cardiovascular disease

Zhongchao Inc. announced the pricing of its initial public offering of 3,000,000 Class A ordinary shares at a public offering price of $4.00 per share.

On February 7, 2020, the Government of Canada repatriated individuals and their families from Wuhan, China, which is the epicentre of the outbreak of novel coronavirus.

Intra-Cellular Therapies, Inc. announced the grant to four new employees of inducement stock options to purchase an aggregate of 6,688 shares of its common stock and restricted stock units for an aggregate of 6,681 shares of its common stock under its 2019 Inducement Award Plan.

The U.S. Food and Drug Administration authorized marketing of the first test to detect a genetic condition known as Fragile X Syndrome, the most common known cause of inherited developmental delay and intellectual disability.

Genprex, Inc., a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, announced that it closed its previously announced common stock offering priced at-the-market under Nasdaq rules.

Methodist Le Bonheur Healthcare recently launched Welcome Bluff City Baby, a pilot program designed to encourage reading and literacy interaction from birth.

In two clinical studies (PROMISE-1 in episodic migraine and PROMISE-2 in chronic migraine), VYEPTI met its primary endpoint: decrease in mean monthly migraine days (MMD) over months 1-3.

LONDON, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its audited financial results for the full year ended December 31, 2019 on Thursday, February 27, 2020 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss the full year financial results and provide a corporate update. To participate, please d

Following the outbreak of Covid-19 novel coronavirus, Zoomlion Heavy Industry Science and Technology Co, (01157.HK) - a leading Chinese maker of engineering and agricultural equipment - immediately setup a Prevention and Control Team led by President Mr. Zhan Chunxin to coordinate donations and support the construction of emergency hospitals while ensuring workplace safety for returning employees.